Viewing nowPcliglon Tablet (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
SS Pharm Co., Ltd.

MFDS item code 200703464 · Notified 2007.03.27 · Insurance code 652604810
Improvement of blood glucose control in type 2 diabetes mellitus
This medication assists in controlling blood sugar levels in patients with type 2 diabetes, functioning as an adjunct to dietary and exercise therapy. It can be used alone or in combination with other medications to enhance its effectiveness. This helps to improve blood sugar control and aids in diabetes management.
This drug is administered orally once daily, regardless of meals. Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, if glycemic control does not worsen in patients with diabetes, this drug should be administered for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. 1. Monotherapy In patients whose blood glucose is not adequately controlled by diet and exercise, this drug may be initiated as monotherapy with pioglitazone 15 mg once daily. If the initial dose of this drug does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylurea: This drug may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be maintained when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment under General Precautions). Do not initiate treatment with this drug if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (see Effects on the Liver under Adverse Reactions and General Precautions).
Use is not recommended in children under 18 years of age because there is no experience with use in this age group.
This medication is used for the treatment of type 2 diabetes and helps to enhance insulin function. However, it may put a strain on the heart, so it should not be used in patients with or a history of heart failure. During treatment, sudden weight gain, shortness of breath, and swelling, which are symptoms of heart failure, should be carefully monitored. If these symptoms occur, consult a doctor immediately. Additionally, this medication can cause fluid retention and may lead to edema, so caution is required in patients with swelling. It should not be administered to bladder cancer patients or those with a history of bladder cancer, and if hematuria or urination disorders occur during treatment, inform your doctor immediately. Patients with impaired liver function or severe kidney disorders should avoid this medication. Women who are pregnant or may become pregnant should not take this medication, and premenopausal women should use appropriate contraception as this medication may stimulate ovulation, increasing the risk of pregnancy. The risk of hypoglycemia is present if this medication is used with insulin or other hypoglycemic agents, so monitor blood sugar levels closely. Furthermore, long-term use may lead to weight gain and an increased risk of fractures, hence regular health checks are necessary. While on this medication, regular blood sugar and liver function tests should be performed, and if any abnormal symptoms appear, consult healthcare staff immediately. The safety of this medication has not been established for children, and elderly patients should use with caution. Lastly, store this medication out of reach of children and keep in the original container.
Congestive heart failure, excessive and rapid weight change, shortness of breath, edema, fluid retention, swelling, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, back pain, dizziness, diarrhea, increased serum creatine kinase, heart failure, limb pain, chest pain, death due to cardiovascular causes, hospitalization due to worsening congestive heart failure, emergency room visit due to congestive heart failure, cardiovascular adverse events, dizziness, worsening of liver disease, urticaria, eczema, joint pain, knee abnormalities, arm weakness syndrome, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, hypertension, heart failure, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, heart failure, bladder cancer, fatigue, loss of appetite, discomfort in the right upper abdomen, dark urine, jaundice, liver damage, macular edema, fracture, weight gain, elevated serum ALT levels, elevated serum bilirubin levels
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that blocks light and air, avoiding areas with high humidity. It is best to maintain a storage temperature between 15 to 30 degrees Celsius, with around 25 degrees being optimal.
This is a round and convex tablet that is white to off-white in color.
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
SS Pharm Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.